Intratumoral heterogeneity of HER2 gene amplification in occult breast cancer.
Ling Xin,Hong Zhang,Shuang Zhang,Jingming Ye,Ting Li,Yinhua Liu
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20132597
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:Occult breast cancer (OBC) is an uncommon type of breast cancer, with palpable masses in the axillary area as the initial symptom. We report a case of OBC with HER2 genetic heterogeneity and discuss the impact of an unusual HER2 amplification pattern. A 56-year-old female was discovered a palpable mass in the right axillary area. She underwent a lymph node excisional biopsy at another hospital approximately one month before referral to our hospital service for further evaluation. The biopsy showed lymph tissue with tumor cell infiltrating in the form of sheets or nests. The tumor cells were larging in size, obviously atypical, and showed prominent nucleoli and intracellular keratosis. Mammography, chest X-ray, chest computed tomography (CT), abdominal ultrasonography (US), and positron emission tomography-CT (PET-CT), which were also performed at the initial hospital, showed no abnormal findings. Our initial physical examination of the patient revealed no abnormalities other than a surgical scar from the excisional biopsy found in the right axilla, and no palpable mass or suspicious skin change was found on either breast. The patient had no history of cancer. However, the patient's sister had died of breast cancer. Breast US showed a hypoechoic nodule deep inside the right nipple (1.1 cm × 0.8 cm). The patient then underwent ultrasound-guided core needle biopsy (CNB) of the hypoechoic nodule inside the right breast. The pathological result was “fibroadenoma-like changes,” a benign lesion. Immunohistochemistry (IHC) of the lymph node cut down at the initial hospital showed 34βE12+++, CK7+++, mammaglobin-, ER-, PR-, HER2+, CD56-, synaptophysin-, and Ki67: 90%. Thus, metastatic poorly differentiated carcinoma with squamous cell carcinoma-like differentiation was considered. The patient was diagnosed as having (right) axillary lymph node metastasis and OBC. Since US and mammography did not show any malignant lesion in the breast, dynamic contrast-enhanced MRI (DCE-MRI) was performed to find the primary site. DCE-MRI showed abnormal signal intensity in the upper quadrant of the right breast, with a type II time-intensity curve. In addition, enhanced lesions were detected in the upper outer quadrant (near the axilla) of the right breast and the possibility of lymph node metastasis could not be ruled out. According to the findings, breast US was repeated and two suspicious nodules (0.4 cm × 0.3 cm and 0.6 cm × 0.4 cm) were found near the abnormal area as shown in DCE-MRI. On November 20th, 2012, the patient underwent ultrasound-guided extended excision biopsy of the mass in the right breast. Pathology of the intraoperative frozen section showed a poorly differentiated carcinoma (4 mm in diameter) and a fibroadenoma (6 mm in diameter). A right modified radical mastectomy was then performed. The postoperative pathological report revealed an invasive ductal carcinoma (4 mm in diameter; NOS, Grade III, with 4 in 18 axillary lymph nodes positive for metastasis). IHC showed ER-, PR-, HER2++, and Ki67: 90%. Fluorescence in situ hybridization (FISH) showed heterogeneous HER2 gene amplification, which meant HER2 signals were in a cluster pattern with a HER2/CEP17 ratio of more than 2.20 in about 40% of tumor cells. The postoperative diagnosis was breast cancer pT1aN2M0. The patient subsequently underwent adjuvant chemotherapy (doxorubicin and cyclophosphamide, four cycles + taxane, four cycles) plus trastuzumab which was continued for one year after the surgery. Sequential radiotherapy was scheduled after chemotherapy and trastuzumab. OBC, initially reported by Halsted et al in 1907, accounts for 0.3%-1.0% of all women with newly diagnosed breast cancer.1 Its primary lesion cannot be identified through physical examination and usual radiologic examinations (such as breast US and mammography). The 2011 ESMO Guidelines reported that 50%-70% of OBC can be identified by breast MRI. Therefore, breast DCE MRI is strongly recommended when the standardized diagnostic work-up failed to identify the site of the primary tumor. OBC can migrate to the axillary lymph nodes even in its early stages and therefore the prognosis is usually poor, with 5- and 10-year survival rates similar to Stage III breast cancer.2 The 2011 ESMO Guidelines recommend a multidisciplinary treatment approach for OBC: total mastectomy with axillary lymph node dissection along with adjuvant chemotherapy and adjuvant radiotherapy of the lymphatic drainage area. Our patient had already undergone modified radical mastectomy. Although the primary lesion was small (T1a), five axillary lymph nodes were involved, indicating that the tumor should be staged as IIIA (N2). The histological stage was interpreted to be III, and the patient was at a high risk of recurrence. Therefore, recommended treatment included sequential taxane and anthracyclinebased chemotherapy as well as sequential radiotherapy of the lymphatic drainage area. HER2 status is part of the recommended work-up before the treatment for all breast cancer patients. Positive for HER2 is either IHC HER2+++, or HER2++ with FISH amplified (ratio of HER2/CEP17 of >2.20 or average HER2 gene copy number >6 signals/nucleus).3 Heterogeneous amplification of HER2 gene presented in our case is an unusual amplification pattern of HER2 gene. It refers to two different or mixed clones of cancer cells with different HER2 amplification patterns inside the same tumor. In 2009, the College of American Pathologists (CAP) redefined heterogeneous amplification of HER2 as amplification in 5%-50% of cancer cells with an HER2/CEP17 ratio of more than 2.20.4 Previous studies showed no significant differences in 5-year survival rates in patients with 5%-30% of tumor cells with HER2/CEP17 ratios >2.20, but outcome progressively worsened in all amplified cases with 30%-50% of cells with HER2/CEP17 ratios >2.20.5 The amplification percentage of cancer cells does affect the prognosis. Therefore, pathologists and FISH technicians should pay full attention to the heterogeneity of HER2 gene. It is recommended that additional cells and/or areas should be counted if there is evidence of HER2 genetic heterogeneity. However, limited studies have explored the treatment protocols for patients with heterogeneous HER2 gene amplification. In our case, 40% of the tumor cells demonstrated HER2 gene amplification, and anti-HER2 therapy was recommended because the patient was expected to benefit from the treatment.